EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Epitranscriptomic regulation in the progression of cancer and platinum resistance

Pavol Harvanik, Terézia Hudáková, Martina Šemeláková, Zuzana Solárová, Peter Solár

Advances in Medical Sciences · 2026-09 · 71 (2) · 269-277

DOI: 10.1016/j.advms.2026.07.002 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Advances in Medical Sciences, 2026-09. Verfasst von Pavol Harvanik und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Biology, Faculty of Medicine, P. J. Šafárik University in Košice, Košice, Slovakia. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 148 Literaturangaben. Gefördert von: Vedecká Grantová Agentúra MŠVVaŠ SR a SAV, Ministry of Education Science Research and Sport of the Slovak Republic.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Epitranscriptomic regulation has emerged as a critical mechanism in cancer biology, particularly in the development of chemoresistance. RNA modifications including N6-methyladenosine (m6A), 5-methylcytosine (m5C), N1-methyladenosine (m1A), 7-methylguanosine (m7G), pseudouridine (Ψ), and A-to-I editing dynamically control mRNA stability, splicing, translation, and degradation. RNA-modifying proteins called 'writers,' 'erasers,' and 'readers' regulate post-transcriptional networks to enable tumor adaptation and chemoresistance. In platinum-resistant tumors, epitranscriptomic changes modulate DNA damage response, apoptosis, drug efflux, and detoxification pathways. Preclinical studies demonstrate that pharmacological inhibition of key regulators, such as METTL3 inhibitors (STC-15, STM2457, UZH2) or FTO inhibitors, can sensitize tumors to platinum drugs and stimulate anti-tumor immunity. However, clinical translation remains limited by off-target effects, toxicity, and highly context-specific responses. Epitranscriptomic profiling may help identify novel biomarkers and guiding precision strategies to overcome chemoresistance.

Schlagwörter

Stichwörter der Autor:innen

Antineoplastic agentsBiomarkersDrug resistanceNeoplasmsRNA methylation

Autor:innen und Institutionen

  • Department of Medical Biology, Faculty of Medicine, P. J. Šafárik University in Košice, Košice, Slovakia.
  • Department of Pharmacology, Faculty of Medicine, P. J. Šafárik University in Košice, Košice, Slovakia.
  • Department of Medical Biology, Faculty of Medicine, P. J. Šafárik University in Košice, Košice, Slovakia. Electronic address: peter.solar@upjs.sk.

Förderung

  • Vedecká Grantová Agentúra MŠVVaŠ SR a SAV
  • Ministry of Education Science Research and Sport of the Slovak Republic

Zitieren

APA

Harvanik, P., Hudáková, T., Šemeláková, M., Solárová, Z., & Solár, P. (2026). Epitranscriptomic regulation in the progression of cancer and platinum resistance. Advances in Medical Sciences, 71(2), 269-277. https://doi.org/10.1016/j.advms.2026.07.002

Vancouver

Harvanik P, Hudáková T, Šemeláková M, Solárová Z, Solár P. Epitranscriptomic regulation in the progression of cancer and platinum resistance. Advances in Medical Sciences. 2026;71(2):269-277. doi:10.1016/j.advms.2026.07.002

BibTeX
@article{Harvanik2026,
  author = {Harvanik, Pavol and Hudáková, Terézia and Šemeláková, Martina and Solárová, Zuzana and Solár, Peter},
  title = {Epitranscriptomic regulation in the progression of cancer and platinum resistance},
  journal = {Advances in Medical Sciences},
  year = {2026},
  volume = {71},
  number = {2},
  pages = {269--277},
  doi = {10.1016/j.advms.2026.07.002}
}
Kostenlos starten →